Cargando…

P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE

Detalles Bibliográficos
Autores principales:	Lehne, M., Kortüm, K.M., Zamagni, E., d’Estrube, T., Shukla, S., Zhuleku, E., Ghiani, M., Hanna, M., Maywald, U., Wilke, T., Perera, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171476/ http://dx.doi.org/10.1097/01.HS9.0000936288.27701.b7

Ejemplares similares

P958: REAL-WORLD TREATMENT PATTERNS IN PATIENTS INITIATING THIRD-LINE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN GERMANY, ITALY, THE UK, FRANCE, AND SPAIN
por: Ramasamy, Karthik, et al.
Publicado: (2023)

Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)
por: Ghiani, Marco, et al.
Publicado: (2023)

P21 Social Distancing and Trends in Influenza Hospitalization during the COVID-19 Outbreak: A Difference-in-Difference Analysis of German Claims Data
por: Pacis, S, et al.
Publicado: (2022)

POSA32 Early COVID-19 Pandemic in Germany: Patient Characteristics and Clinical Outcomes
por: Pacis, S, et al.
Publicado: (2022)

EPH35 Post-COVID Conditions in Hospitalized COVID-19 Patients in Germany
por: Pacis, S, et al.
Publicado: (2022)

P24: EXPERT PERSPECTIVES OF UNMET NEED IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE LENALIDOMIDE-SPARING REGIMENS IN EUROPE
por: Mateos, M, et al.
Publicado: (2022)

Burden of disease among patients with prevalent Crohn’s disease: results from a large German sickness fund
por: Zhuleku, Evi, et al.
Publicado: (2023)

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data
por: Zhuleku, Evi, et al.
Publicado: (2022)

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
por: Nooka, A., et al.
Publicado: (2023)

Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
por: Raab, Marc S., et al.
Publicado: (2023)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
por: Terpos, Evangelos, et al.
Publicado: (2022)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEW
por: Hanna, M., et al.
Publicado: (2023)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia
por: Cook, Gordon, et al.
Publicado: (2021)

POSB189 Mental Health in COVID Times: A Quasi-Experimental Analysis of the Impact of Lockdown Measures on Mental Healthcare Use in Germany
por: Ghiani, M, et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
por: Leleu, X, et al.
Publicado: (2017)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
por: Bhatt, Parva, et al.
Publicado: (2023)

Healthcare resource utilization and associated cost of patients with bone metastases from solid tumors who are naïve to bone-targeting agents: a comparative analysis of patients with and without skeletal-related events
por: Hardtstock, Fränce, et al.
Publicado: (2021)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer?
por: Wilke, Thomas, et al.
Publicado: (2018)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data
por: Knapp, Rachel K., et al.
Publicado: (2021)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma
por: Pierre, Amy E., et al.
Publicado: (2020)

Repeat administration of high dose melphalan in relapsed myeloma.
por: Mansi, J. L., et al.
Publicado: (1993)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
por: Yang, Wen-Chi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sl1gg4v8lbvhp9vnk9aotmehln